AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma

Authors :: Francesco Tovoli
Pietro Lampertico
Enrico Galmozzi
Luca Faloppi
Carmine Tinelli
Massimo Iavarone
Fabio Piscaglia
Giorgia Marisi
Angelo Sangiovanni
Andrea Casadei-Gardini
A. De Silvestri
A. Cimino
Stefano Cascinu
M. Scartozzi
Fabio Facchetti
Luca Ielasi
Source :: Digestive and Liver Disease. 51:e38
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Sorafenib
Oncology
medicine.medical_specialty
Hepatology
business.industry
Gastroenterology
medicine.disease
Hepatocellular carcinoma
Internal medicine
medicine
Adverse effect
business
Gene
Dose Modification
medicine.drug

Tools